Welcome to the Cardious website. Within this site you will find a description of Cardious Inc., an emerging medical device company.  We are focused on the development of a less invasive aortic heart valve therapy that allows a traditional heart valve (selected by the surgeon) to be surgically installed into a beating heart.

We encourage your participation during our development process, especially if you are a cardiac surgeon, a biomedical professional, or an active investor.  To that end, we have included a weblog (blog) feature. We will be posting articles (and opinions) about our product and will be looking forward to your comments and responses.  After reviewing our site, please contact us if you would like to learn more about our company.

Best Regards,
Jim Pokorney, President and CEO


Cardious intends to provide the Cardiac Surgeon with the implants and associated tool needed to safely and effectively relieve aortic heart valve stenosis without stopping the heart while still using the same trusted clinically proven prosthetic heart valve the surgeon has historically implanted.  Our business is based on the following fundamental beliefs:

  • We believe a successful aortic valve surgery business should revolve around experienced surgeons safely implanting proven, state of the art heart valves – even if the procedure is done “off pump”.
  • We believe all cardiac surgeons in all operating rooms around the world should be able to confidently provide patients an “off pump” procedure.
  • We believe an “off pump” aortic valve procedure should not be constrained by native valve anatomy, limited to “centers of excellence”, carry a high risk profile, or require an extremely high, perhaps unsustainable, selling price to be profitable.

Company Summary
Cardious is a medical device company headquartered in Northfield, Minnesota.  It was founded to develop and commercialize an Aortic Valve Bypass Graft System for use as a minimally invasive, beating heart alternative to traditional aortic valve replacement therapy.

Cardious has developed a strong intellectual property portfolio — laying claim to essential proprietary methods, implants, and associated tools required to successfully perform this procedure on a beating heart using a commercially available prosthetic heart valve.

Current work is focused on the final design, fabrication, testing, and documentation required to support in vitro and in vivo animal studies leading to a limited human trial.